Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2

Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Mi...

Full description

Saved in:
Bibliographic Details
Published inStem cell research & therapy Vol. 10; no. 1; pp. 381 - 14
Main Authors Xu, Haiyang, Zhao, Guifang, Zhang, Yu, Jiang, Hong, Wang, Weiyao, Zhao, Donghai, Hong, Jin, Yu, Hongquan, Qi, Ling
Format Journal Article
LanguageEnglish
Published England BioMed Central 16.12.2019
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.
AbstractList Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors.BACKGROUNDMesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors.Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings.METHODSMicroarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings.miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development.RESULTSmiR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development.Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.CONCLUSIONCollectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.
Abstract Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Methods Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. Results miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Conclusion Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.
Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Methods Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. Results miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Conclusion Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.
Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.
ArticleNumber 381
Author Yu, Hongquan
Zhao, Guifang
Hong, Jin
Zhang, Yu
Zhao, Donghai
Jiang, Hong
Qi, Ling
Wang, Weiyao
Xu, Haiyang
Author_xml – sequence: 1
  givenname: Haiyang
  surname: Xu
  fullname: Xu, Haiyang
– sequence: 2
  givenname: Guifang
  surname: Zhao
  fullname: Zhao, Guifang
– sequence: 3
  givenname: Yu
  surname: Zhang
  fullname: Zhang, Yu
– sequence: 4
  givenname: Hong
  surname: Jiang
  fullname: Jiang, Hong
– sequence: 5
  givenname: Weiyao
  surname: Wang
  fullname: Wang, Weiyao
– sequence: 6
  givenname: Donghai
  surname: Zhao
  fullname: Zhao, Donghai
– sequence: 7
  givenname: Jin
  surname: Hong
  fullname: Hong, Jin
– sequence: 8
  givenname: Hongquan
  surname: Yu
  fullname: Yu, Hongquan
– sequence: 9
  givenname: Ling
  surname: Qi
  fullname: Qi, Ling
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31842978$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAUhSNUREvpA7BBltiwCfVP4iQbpKoqtFIBCYGQ2Fg39k3GoyQebM_A9A14HR6EZ8LplKrtAm9sXX_36NrnPM32Jjdhlj1n9DVjtTwOTPC6yilrclYUMr96lB2wqqxyWTK-d-e8nx2FsKRpCUGpLJ5k-4LVBW-q-iD79R4DTnqxHWEgIeJINA5DbtDbDRqCP11w89VotXefPpzkTIiWhPVq5TEEDKQfbALIyrt-rlg3kY0F8nWKx39-5xoiTnYiwfYTDHbqyQri4gdsSbslEXyPcS6efTvnz7LHHQwBj272w-zL27PPp-f55cd3F6cnl7kuGhHzjnamwpIixwqgMgitMC1yU9YMKXRCFgwo00Z2HS2FbFtqBMgaS46Mt1ocZhc7XeNgqVbejuC3yoFV1wXnewU-Wj2gklx3stYAsuSFZtAyJivDa1GjoabEpPVmp7VatyMajVP0MNwTvX8z2YXq3UbJhpUNK5LAqxsB776vMUQ12jA7ABO6dVBc8KopuKxEQl8-QJdu7dOvXlN1WXIqWaJe3J3odpR_jieA7YDkZwgeu1uEUTUHS-2CpVKw1BwsdZV6qgc92kaIyev0KDv8p_MvlurWNg
CitedBy_id crossref_primary_10_3390_pharmaceutics14051054
crossref_primary_10_1007_s10620_020_06458_1
crossref_primary_10_1111_jcmm_17933
crossref_primary_10_18632_oncotarget_27622
crossref_primary_10_3389_fcell_2024_1459246
crossref_primary_10_1016_j_biopha_2023_115505
crossref_primary_10_1155_2020_8844730
crossref_primary_10_3389_fcell_2020_574940
crossref_primary_10_3389_fonc_2021_733529
crossref_primary_10_1039_D4BM01394H
crossref_primary_10_3390_ijms23020625
crossref_primary_10_1016_j_ncrna_2024_11_004
crossref_primary_10_3389_fcell_2021_740783
crossref_primary_10_1186_s12935_022_02642_7
crossref_primary_10_1186_s12964_020_00623_9
crossref_primary_10_3389_fphar_2024_1438177
crossref_primary_10_1093_hmg_ddac130
crossref_primary_10_3390_pharmaceutics15051439
crossref_primary_10_1002_jcp_30495
crossref_primary_10_3389_fonc_2023_1299384
crossref_primary_10_1002_wrna_1735
crossref_primary_10_2147_JIR_S429532
crossref_primary_10_3389_fbioe_2021_652970
crossref_primary_10_3390_bioengineering10010051
crossref_primary_10_3390_biom14111354
crossref_primary_10_1007_s12032_025_02648_x
crossref_primary_10_1111_jcmm_16970
crossref_primary_10_1007_s10565_022_09759_5
crossref_primary_10_1016_j_apsb_2022_11_019
crossref_primary_10_3390_ijms22073576
crossref_primary_10_3390_cells13070617
crossref_primary_10_1016_j_mtbio_2025_101646
crossref_primary_10_3389_fnmol_2022_1004221
crossref_primary_10_3389_fonc_2022_1047907
crossref_primary_10_1021_acsbiomaterials_3c00212
crossref_primary_10_1016_j_ijbiomac_2023_128722
crossref_primary_10_1007_s10495_021_01674_0
crossref_primary_10_3389_fimmu_2021_813747
crossref_primary_10_1016_j_cellsig_2022_110493
crossref_primary_10_3390_cancers13051157
crossref_primary_10_1093_jpp_rgae086
crossref_primary_10_3390_ijms241210162
crossref_primary_10_1016_j_yexcr_2020_112321
crossref_primary_10_1016_j_ijbiomac_2024_130728
crossref_primary_10_1007_s12015_020_10082_x
crossref_primary_10_3390_cancers12092486
crossref_primary_10_3390_biom14121519
crossref_primary_10_3390_ph17060707
crossref_primary_10_1002_jnr_25134
crossref_primary_10_3390_cancers15245847
crossref_primary_10_1007_s13577_022_00753_x
crossref_primary_10_1016_j_biopha_2021_112532
crossref_primary_10_1080_10799893_2021_1918166
crossref_primary_10_1016_j_jconrel_2021_12_024
crossref_primary_10_34133_research_0421
crossref_primary_10_1080_10717544_2022_2104404
crossref_primary_10_3390_ijms23052745
crossref_primary_10_1016_j_lfs_2024_123150
crossref_primary_10_1016_j_neubiorev_2023_105206
crossref_primary_10_1007_s13205_021_02922_5
crossref_primary_10_1016_j_critrevonc_2021_103547
crossref_primary_10_3389_fimmu_2023_1175118
crossref_primary_10_3892_etm_2021_10950
crossref_primary_10_3389_fcvm_2021_737512
crossref_primary_10_1007_s11010_021_04053_0
crossref_primary_10_1186_s12935_024_03507_x
crossref_primary_10_1002_mco2_49
crossref_primary_10_1007_s10565_021_09652_7
crossref_primary_10_3892_ijo_2024_5712
crossref_primary_10_1155_2021_4907167
crossref_primary_10_3389_fbioe_2022_1019459
crossref_primary_10_1002_sctm_20_0161
crossref_primary_10_18097_pbmc20226806419
crossref_primary_10_1016_j_lfs_2022_121103
crossref_primary_10_1038_s41392_022_01298_z
crossref_primary_10_18632_aging_202923
crossref_primary_10_1002_adma_202005709
crossref_primary_10_1038_s41417_022_00427_8
crossref_primary_10_15252_embj_2021109288
crossref_primary_10_1155_2022_8071343
crossref_primary_10_2147_IJN_S407029
crossref_primary_10_1007_s12094_022_02966_w
crossref_primary_10_1016_j_yexcr_2022_113208
crossref_primary_10_1016_j_vesic_2024_100049
crossref_primary_10_1016_j_bbcan_2022_188700
crossref_primary_10_1007_s10616_024_00631_4
crossref_primary_10_1016_j_bioactmat_2021_05_038
crossref_primary_10_3390_ijms222011187
crossref_primary_10_1038_s41392_022_01134_4
crossref_primary_10_1111_cpr_12833
crossref_primary_10_1186_s10020_024_00857_0
crossref_primary_10_3389_fbioe_2022_956563
crossref_primary_10_1186_s13287_020_01676_w
crossref_primary_10_1186_s13287_022_03212_4
crossref_primary_10_1080_02648725_2023_2204720
crossref_primary_10_1016_j_ajps_2021_08_003
crossref_primary_10_1016_j_biopha_2022_113554
crossref_primary_10_1186_s12935_021_02144_y
crossref_primary_10_1155_2021_5589342
crossref_primary_10_1007_s13346_024_01710_x
crossref_primary_10_1515_oncologie_2023_0482
crossref_primary_10_3390_biomedicines12081822
crossref_primary_10_18632_aging_204513
crossref_primary_10_1016_j_biopha_2021_112187
crossref_primary_10_3390_pharmaceutics13070988
crossref_primary_10_1186_s13287_023_03551_w
crossref_primary_10_1016_j_canlet_2023_216592
crossref_primary_10_3390_ijms23031353
crossref_primary_10_3390_cimb45040208
crossref_primary_10_1186_s13578_021_00620_6
crossref_primary_10_3389_fcell_2023_1255697
crossref_primary_10_18632_aging_202747
crossref_primary_10_1038_s41598_024_68922_6
crossref_primary_10_1016_j_biopha_2023_115405
crossref_primary_10_3390_cells12091247
crossref_primary_10_3390_pharmaceutics14010116
crossref_primary_10_1016_j_jconrel_2023_04_038
crossref_primary_10_3390_ijms222212204
crossref_primary_10_3390_ijms231810972
crossref_primary_10_1007_s11033_021_06687_1
crossref_primary_10_1002_2211_5463_13352
Cites_doi 10.1016/j.biopha.2016.11.053
10.3892/ol.2015.3657
10.1016/j.neuint.2014.06.002
10.1517/14712598.2012.680018
10.18632/oncotarget.9198
10.7717/peerj.4336
10.1186/s13046-017-0567-4
10.1111/j.1365-2990.2010.01132.x
10.18632/oncotarget.10370
10.1371/journal.pone.0092129
10.5483/BMBRep.2018.51.8.105
10.1002/stem.1247
10.1371/journal.pone.0169932
10.3109/07357907.2012.692171
10.1111/jth.12602
10.3390/ijms18020372
10.7717/peerj.4196
10.18632/oncotarget.21311
10.1093/neuonc/nou087
10.18632/oncotarget.9236
10.1006/meth.2001.1262
10.1371/journal.pone.0181346
10.3390/genes9020105
10.1016/j.jns.2013.09.030
10.2741/3952
10.1158/0008-5472.CAN-16-2524
10.12954/PI.12011
10.1593/tlo.13640
10.1007/s10555-010-9222-7
10.18632/oncotarget.868
10.2741/4362
10.1016/j.canlet.2011.10.002
10.18632/oncotarget.424
ContentType Journal Article
Copyright 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13287-019-1446-z
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1757-6512
EndPage 14
ExternalDocumentID oai_doaj_org_article_62cf68caa6524c1ab1167d2838ed0d5e
PMC6915914
31842978
10_1186_s13287_019_1446_z
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
China
Japan
GeographicLocations_xml – name: China
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: ;
  grantid: 81201671
– fundername: ;
  grantid: 201920190201090JC, 20190101006JH, 20180101306JC
GroupedDBID ---
0R~
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ISR
ITC
KQ8
LK8
M1P
M7P
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SBL
SOJ
SV3
TUS
UKHRP
-56
-5G
-BR
3V.
ACRMQ
ADINQ
C24
NPM
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c493t-f0fd7e50e2e7aa7deab3dbe2d581e0af3641a01cd6ff0536bb0d3a68e52e12bc3
IEDL.DBID DOA
ISSN 1757-6512
IngestDate Wed Aug 27 01:27:42 EDT 2025
Thu Aug 21 18:15:29 EDT 2025
Fri Jul 11 06:59:49 EDT 2025
Fri Jul 25 09:41:49 EDT 2025
Thu Jan 02 22:58:55 EST 2025
Tue Jul 01 00:43:23 EDT 2025
Thu Apr 24 22:53:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Glioma
Wnt/β-catenin signaling pathway
Exosomes
MicroRNA-133b
EZH2
Mesenchymal stem cells
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-f0fd7e50e2e7aa7deab3dbe2d581e0af3641a01cd6ff0536bb0d3a68e52e12bc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/62cf68caa6524c1ab1167d2838ed0d5e
PMID 31842978
PQID 2328552061
PQPubID 2040189
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_62cf68caa6524c1ab1167d2838ed0d5e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6915914
proquest_miscellaneous_2327942673
proquest_journals_2328552061
pubmed_primary_31842978
crossref_primary_10_1186_s13287_019_1446_z
crossref_citationtrail_10_1186_s13287_019_1446_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-12-16
PublicationDateYYYYMMDD 2019-12-16
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-16
  day: 16
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Stem cell research & therapy
PublicationTitleAlternate Stem Cell Res Ther
PublicationYear 2019
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References IA Ho (1446_CR7) 2013; 31
WT Kim (1446_CR12) 2013; 1
Z Wu (1446_CR32) 2013; 335
R Domenis (1446_CR30) 2017; 12
JJ Zhang (1446_CR35) 2017; 85
T Yu (1446_CR28) 2017; 8
Mariachiara Zuccarini (1446_CR21) 2018; 9
C Li (1446_CR16) 2016; 7
Q Li (1446_CR3) 2015; 8
N Nohata (1446_CR14) 2012; 3
X Jiang (1446_CR33) 2017; 5
J Sun (1446_CR26) 2017; 36
W Xiong (1446_CR1) 2018; 39
HK Lee (1446_CR34) 2013; 4
Y Wang (1446_CR19) 2016; 7
J Figueroa (1446_CR10) 2017; 77
W Zhu (1446_CR8) 2012; 315
QT Ostrom (1446_CR2) 2014; 16
KJ Livak (1446_CR22) 2001; 25
F Orzan (1446_CR17) 2011; 37
MY Li (1446_CR29) 2017; 33
T Zeng (1446_CR4) 2015; 20
H Ye (1446_CR6) 2012; 30
Cecilia Lässer (1446_CR11) 2012; 12
E van der Pol (1446_CR25) 2014; 12
SA Bergfeld (1446_CR5) 2010; 29
X Fu (1446_CR23) 2018; 6
G Zhang (1446_CR24) 2014; 9
WT Arscott (1446_CR9) 2013; 6
JF Chen (1446_CR36) 2016; 7
L Gao (1446_CR20) 2017; 12
L Chang (1446_CR15) 2015; 10
Ssu-Yin Yen (1446_CR18) 2017; 18
Y Zhang (1446_CR13) 2012; 17
R Kim (1446_CR27) 2018; 51
1446_CR31
References_xml – volume: 8
  start-page: 12234
  issue: 10
  year: 2015
  ident: 1446_CR3
  publication-title: Int J Clin Exp Pathol
– volume: 85
  start-page: 472
  year: 2017
  ident: 1446_CR35
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2016.11.053
– volume: 10
  start-page: 2781
  issue: 5
  year: 2015
  ident: 1446_CR15
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3657
– ident: 1446_CR31
  doi: 10.1016/j.neuint.2014.06.002
– volume: 12
  start-page: S189
  issue: sup1
  year: 2012
  ident: 1446_CR11
  publication-title: Expert Opinion on Biological Therapy
  doi: 10.1517/14712598.2012.680018
– volume: 7
  start-page: 36247
  issue: 24
  year: 2016
  ident: 1446_CR16
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.9198
– volume: 6
  start-page: e4336
  year: 2018
  ident: 1446_CR23
  publication-title: PeerJ
  doi: 10.7717/peerj.4336
– volume: 36
  start-page: 100
  issue: 1
  year: 2017
  ident: 1446_CR26
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-017-0567-4
– volume: 37
  start-page: 381
  issue: 4
  year: 2011
  ident: 1446_CR17
  publication-title: Neuropathol Appl Neurobiol
  doi: 10.1111/j.1365-2990.2010.01132.x
– volume: 7
  start-page: 49450
  issue: 31
  year: 2016
  ident: 1446_CR19
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.10370
– volume: 9
  start-page: e92129
  issue: 3
  year: 2014
  ident: 1446_CR24
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0092129
– volume: 51
  start-page: 406
  issue: 8
  year: 2018
  ident: 1446_CR27
  publication-title: BMB Rep
  doi: 10.5483/BMBRep.2018.51.8.105
– volume: 31
  start-page: 146
  issue: 1
  year: 2013
  ident: 1446_CR7
  publication-title: Stem Cells
  doi: 10.1002/stem.1247
– volume: 39
  start-page: 1939
  issue: 4
  year: 2018
  ident: 1446_CR1
  publication-title: Oncol Rep
– volume: 12
  start-page: e0169932
  issue: 1
  year: 2017
  ident: 1446_CR30
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0169932
– volume: 30
  start-page: 513
  issue: 7
  year: 2012
  ident: 1446_CR6
  publication-title: Cancer Investig
  doi: 10.3109/07357907.2012.692171
– volume: 12
  start-page: 1182
  issue: 7
  year: 2014
  ident: 1446_CR25
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12602
– volume: 18
  start-page: 372
  issue: 2
  year: 2017
  ident: 1446_CR18
  publication-title: International Journal of Molecular Sciences
  doi: 10.3390/ijms18020372
– volume: 5
  start-page: e4196
  year: 2017
  ident: 1446_CR33
  publication-title: PeerJ
  doi: 10.7717/peerj.4196
– volume: 8
  start-page: 98348
  issue: 58
  year: 2017
  ident: 1446_CR28
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.21311
– volume: 16
  start-page: 896
  issue: 7
  year: 2014
  ident: 1446_CR2
  publication-title: Neuro-Oncology
  doi: 10.1093/neuonc/nou087
– volume: 7
  start-page: 41540
  issue: 27
  year: 2016
  ident: 1446_CR36
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.9236
– volume: 25
  start-page: 402
  issue: 4
  year: 2001
  ident: 1446_CR22
  publication-title: Methods.
  doi: 10.1006/meth.2001.1262
– volume: 12
  start-page: e0181346
  issue: 8
  year: 2017
  ident: 1446_CR20
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0181346
– volume: 9
  start-page: 105
  issue: 2
  year: 2018
  ident: 1446_CR21
  publication-title: Genes
  doi: 10.3390/genes9020105
– volume: 335
  start-page: 191
  issue: 1–2
  year: 2013
  ident: 1446_CR32
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2013.09.030
– volume: 17
  start-page: 700
  year: 2012
  ident: 1446_CR13
  publication-title: Front Biosci
  doi: 10.2741/3952
– volume: 77
  start-page: 5808
  issue: 21
  year: 2017
  ident: 1446_CR10
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2524
– volume: 1
  start-page: 3
  issue: 1
  year: 2013
  ident: 1446_CR12
  publication-title: Prostate Int
  doi: 10.12954/PI.12011
– volume: 6
  start-page: 638
  issue: 6
  year: 2013
  ident: 1446_CR9
  publication-title: Transl Oncol
  doi: 10.1593/tlo.13640
– volume: 29
  start-page: 249
  issue: 2
  year: 2010
  ident: 1446_CR5
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-010-9222-7
– volume: 4
  start-page: 346
  issue: 2
  year: 2013
  ident: 1446_CR34
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.868
– volume: 20
  start-page: 1104
  year: 2015
  ident: 1446_CR4
  publication-title: Front Biosci
  doi: 10.2741/4362
– volume: 315
  start-page: 28
  issue: 1
  year: 2012
  ident: 1446_CR8
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2011.10.002
– volume: 33
  start-page: 180
  issue: 3
  year: 2017
  ident: 1446_CR29
  publication-title: Zhonghua Shao Shang Za Zhi
– volume: 3
  start-page: 9
  issue: 1
  year: 2012
  ident: 1446_CR14
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.424
SSID ssj0000330064
Score 2.5358162
Snippet Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by...
Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell...
Abstract Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 381
SubjectTerms Bone marrow
Cell interactions
Cell migration
Cell proliferation
Exosomes
EZH2
Fluorides
Glioma
Glioma cells
Immunoglobulins
Laboratory animals
Medical prognosis
Mesenchymal stem cells
Mesenchyme
Metastases
MicroRNA-133b
MicroRNAs
miRNA
Nervous system
Penicillin
Plasmids
Proteins
Radiation therapy
Signal transduction
Stem cells
Therapeutic applications
Tumors
Wnt protein
Wnt/β-catenin signaling pathway
β-Catenin
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagCIkL4r-BgozECcla23Gc5IQKarVCogdExYpL5J9xu1KbLM1uYfsGvA4PwjPhSbKBRahXeyJZmf_x5xlCXqW5Dc6kkmlfWqZ8zFOi3AQmM-BBcG7zHiB7pKfH6v0smw0Ft3aAVW5sYmeofeOwRj6Jnr_IMhndz5vFV4ZTo_B2dRihcZPcwtZlCOnKZ_lYY-ExWY8ud7jMFIWetDH5KhBrWTJMhNjVljvquvb_L9T8FzH5lws6vEfuDrEj3e-ZfZ_cgPoBud1Pk1w_JD8-4Esid7o-j0TYn5liVZ75KGOX4Cl8b9oGt84Rg_fxaJ_FxNHSdrXosLDQ0pOzeSSgHWSrb9dBL-eGfq6Xk18_GUKn6nlNEfFh8BE7xWnG38ya2jXtAeW4ePBlKh-R48ODT--mbJi0wJwq0yULPPgcMg4ScmNyD8am3oL0WSGAm5BqJQwXzusQotZqa7lPjS4gkyCkdeljslM3NewSyqHMHAgAF0Bxp6xyRdBWKRkgpMImhG9-eOWGNuQ4DeOs6tKRQlc9j6rIowp5VF0l5PX4yaLvwXEd8Vvk4kiI7bO7hebipBq0sdLSBV04Y3QmlRPG4m2Uj5FWAZ77DBKyt5GBatDptvojgQl5OW5HbURmmhqaVUcTDZzUeZqQJ73IjCeJ1jM6_7xISL4lTFtH3d6p56ddx29dxqhTqKfXH-sZuSM7yZZM6D2ys7xYwfMYMi3ti04vfgOcbxpq
  priority: 102
  providerName: ProQuest
Title Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2
URI https://www.ncbi.nlm.nih.gov/pubmed/31842978
https://www.proquest.com/docview/2328552061
https://www.proquest.com/docview/2327942673
https://pubmed.ncbi.nlm.nih.gov/PMC6915914
https://doaj.org/article/62cf68caa6524c1ab1167d2838ed0d5e
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELagCIkL4r8LJTISJyQrttfr3RwblCpCIkIRFVEvK_-MaaR2U7FJIX0DXqcP0mdivLuNEoTgwmUP9qzk9Xz2zKw_zxDyNs1tcCaVTPuBZcpjnIK4CUxmwIPg3OYtQXaix8fqwyybbZX6ipywNj1wO3F9LV3QhTNGZ1I5YWw8OPBoFAvw3GcQd1-0eVvBVLMHY5iOxrY7xhSF7tcYdhWRZTlgMQRiVzuGqMnX_ycn83eu5JbxOXpEHnZeIz1sR_uY3IHqCbnf1pFcPyU_P8Y7RO50fY5CMTMzjf_jmUd0XYKn8GNRL2LXeWTfTSeHDENGS-vVRcOChZp-PZujAG3IWm2iDno5N_RLtezfXLNImqrmFY1cDxOvr9NYx_i7WVO7pi2VPDaOTsbyGTk-Gn1-P2ZdjQXm1CBdssCDzyHjICE3JvdgbOotSJ8VArgJqVbCcOG8DgHXq7aW-9ToAjIJQlqXPid71aKCfUI5DDIHAsAFUNwpq1wRtFVKBgipsAnhtxNeui4BeayDcVY2gUihy1ZHJeqojDoqrxLybvPKRZt942_Cw6jFjWBMnN00IJzKDk7lv-CUkINbDJTdaq5L9DqLLJPo-iTkzaYb12FUpqlgsWpkcGuTOk8T8qKFzGYkuG-i2c-LhOQ7YNoZ6m5PNT9tcn3rAfqbQr38H9_2ijyQDf4lE_qA7C2_reA1ulRL2yN381neI_eGo8mnaa9ZS_icDk9-ASYEJvE
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVgguiH8CBYwEFySrju042QNCLWy1pe0KVa2ouAT_jNuV2mRpdlu2b8DLcOBBeCbsJLuwCPXWazyJrMzn-bE_zyD0kqfaGcUZkbaribA-T_G4cYQlQF1MqU4bguxA9vfFh4PkYAn9mN2FCbTKmU2sDbUtTdgjX_WeP0sS5t3P29FXErpGhdPVWQuNBhZbMD33KVv1ZvO91-8rxjZ6e-_6pO0qQIzo8jFx1NkUEgoMUqVSC0pzq4HZJIuBKseliBWNjZXOeYRKranlSmaQMIiZNtx_9xpaFtynMh20vN4bfNyd7-pQzoOTb49P40yuVj7dywK7s0tC6kUuFhxg3Sfgf8HtvxzNv5zexm10q41W8VoDrztoCYq76HrTv3J6D33fCXeXzNH0xAuFitA4nAMQ61F9BhbDt7Iqw9BJYP3tDtaIT1U1riajmn0LFT48HnoBXJPEmgIh-Gyo8KdivPrrJwlkrWJY4MAxUeHaPA79k8_VFOspbijs4WHvc5_dR_tXooUHqFOUBTxCmEI3MRADGAeCGqGFyZzUQjAHjsc6QnT2w3PTFj4P_TeO8zoBymTe6Cj3OsqDjvKLCL2evzJqqn5cJrwetDgXDAW76wfl6WHerv9cMuNkZpSSCRMmVjqcf1kf22VgqU0gQiszDOStFanyP5iP0Iv5sF__QZmqgHJSy3iTymTKI_Swgcx8Jt5e-3AjzSKULoBpYaqLI8XwqK4xLrs-zo3F48un9Rzd6O_tbOfbm4OtJ-gmq1HOSCxXUGd8OoGnPmAb62ftKsHoy1UvzN-UBVsv
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+stem+cell-derived+exosomal+microRNA-133b+suppresses+glioma+progression+via+Wnt%2F%CE%B2-catenin+signaling+pathway+by+targeting+EZH2&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Xu%2C+Haiyang&rft.au=Zhao%2C+Guifang&rft.au=Zhang%2C+Yu&rft.au=Jiang%2C+Hong&rft.date=2019-12-16&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-019-1446-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13287_019_1446_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon